Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-24 | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W
(Director) |
M | Common Stock | A | 2893 | $39.35 - $39.35 | $113,839 |
| 2024-03-25 | LIGAND PHARMACEUTICALS INC | Davis Todd C
(Chief Executive Officer) |
M | Common Stock | A | 16015 | $46.20 - $68.51 | $919,145 |
| 2024-03-05 | LIGAND PHARMACEUTICALS INC | Sabba Stephen L
(Director) |
S | Common Stock | D | 1893 | $74.30 - $74.30 | $140,649 |
| 2024-03-05 | LIGAND PHARMACEUTICALS INC | Sabba Stephen L
(Director) |
M | Common Stock | A | 2893 | $0.00 - $0.00 | $0 |
| 2024-03-05 | LIGAND PHARMACEUTICALS INC | Aryeh Jason
(Director) |
M | Common Stock | A | 2893 | $39.35 - $39.35 | $113,839 |
| 2024-02-27 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CHIEF LEGAL OFFICER &) |
A | Common Stock | A | 7208 | $0.00 - $0.00 | $0 |
| 2024-02-27 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(PRESIDENT & CHIEF OPERATING) |
A | Common Stock | A | 14416 | $0.00 - $0.00 | $0 |
| 2024-02-28 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
S | Common Stock | D | 140 | $88.46 - $88.46 | $12,384 |
| 2024-02-28 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
M | Common Stock | A | 1264 | $55.75 - $58.49 | $71,563 |
| 2024-02-27 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
A | Common Stock | A | 7208 | $0.00 - $0.00 | $0 |
| 2024-02-27 | LIGAND PHARMACEUTICALS INC | Davis Todd C
(CHIEF EXECUTIVE OFFICER) |
A | Common Stock | A | 32436 | $0.00 - $0.00 | $0 |
| 2024-02-15 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CHIEF LEGAL OFFICER &) |
F | Common Stock | D | 593 | $74.65 - $74.65 | $44,267 |
| 2024-02-15 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(PRESIDENT & CHIEF OPERATING) |
F | Common Stock | D | 4778 | $74.65 - $74.65 | $356,677 |
| 2024-02-15 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
F | Common Stock | D | 1479 | $74.65 - $74.65 | $110,407 |
| 2024-02-15 | LIGAND PHARMACEUTICALS INC | Davis Todd C
(CHIEF EXECUTIVE OFFICER) |
F | Common Stock | D | 1381 | $74.65 - $74.65 | $103,091 |
| 2023-12-29 | LIGAND PHARMACEUTICALS INC | Reardon Andrew
(CHIEF LEGAL OFFICER &) |
J | Common Stock | A | 179 | $60.71 - $60.71 | $10,866 |
| 2024-01-02 | LIGAND PHARMACEUTICALS INC | Korenberg Matthew E
(PRESIDENT & CHIEF OPERATING) |
F | Common Stock | D | 2917 | $72.31 - $72.31 | $210,928 |
| 2023-12-05 | LIGAND PHARMACEUTICALS INC | Espinoza Octavio
(Chief Financial Officer) |
F | Common Stock | D | 1269 | $59.61 - $59.61 | $75,645 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |